These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28595535)

  • 1. Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease.
    Kitrou P; Katsanos K; Karnabatidis D; Reppas L; Brountzos E; Spiliopoulos S
    Curr Vasc Pharmacol; 2017; 15(5):430-445. PubMed ID: 28595535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic treatment in peripheral artery disease.
    Olinic DM; Tataru DA; Homorodean C; Spinu M; Olinic M
    Vasa; 2018 Feb; 47(2):99-108. PubMed ID: 29160765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
    Poredos P; Jezovnik MK
    Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotics in stable peripheral artery disease.
    Kaplovitch E; Rannelli L; Anand SS
    Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Factors for Suboptimal Utilization of Statins and Antiplatelet Therapy in Patients Undergoing Revascularization for Symptomatic Peripheral Arterial Disease.
    Meltzer AJ; Sedrakyan A; Connolly PH; Ellozy S; Schneider DB;
    Ann Vasc Surg; 2018 Jan; 46():234-240. PubMed ID: 28602895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease.
    Arya S; Khakharia A; Binney ZO; DeMartino RR; Brewster LP; Goodney PP; Wilson PWF
    Circulation; 2018 Apr; 137(14):1435-1446. PubMed ID: 29330214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy in peripheral artery disease.
    Foley TR; Waldo SW; Armstrong EJ
    Vasc Med; 2016 Apr; 21(2):156-69. PubMed ID: 26823456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD.
    Govsyeyev N; Nehler MR; Hiatt WR; Bonaca MP
    Curr Cardiol Rep; 2020 Jan; 22(3):13. PubMed ID: 31997026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.
    De Luca L; Bonaca MP; Magnani G
    Expert Rev Cardiovasc Ther; 2020 Dec; 18(12):881-889. PubMed ID: 33021875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor for the treatment of peripheral arterial disease.
    Chong AY; So DY
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1737-43. PubMed ID: 25376000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription of Pharmacotherapy and the Incidence of Stroke in Patients With Symptoms of Peripheral Artery Disease.
    Nastasi DR; Smith JR; Moxon JV; Trollope A; Golledge J
    Stroke; 2018 Dec; 49(12):2953-2960. PubMed ID: 30571405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging drug treatment strategies for peripheral arterial disease.
    Essa H; Torella F; Lip GYH
    Expert Opin Pharmacother; 2020 Sep; 21(13):1603-1616. PubMed ID: 32558590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)].
    Espinola-Klein C
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1060-1064. PubMed ID: 30060273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Peripheral arterial disease: Treatment].
    Desormais I; Aboyans V; Pesteil F; Lacroix P
    Presse Med; 2018 Jan; 47(1):56-61. PubMed ID: 29273182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials.
    Ward R; Long C; Patel MR; Jones WS
    Clin Cardiol; 2018 Jan; 41(1):137-143. PubMed ID: 29355992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy for postinterventional management of peripheral arterial disease.
    Zavgorodnyaya D; Knight TB; Daley MJ; Teixeira PG
    Am J Health Syst Pharm; 2020 Feb; 77(4):269-276. PubMed ID: 31930282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
    Azarbal A; Clavijo L; Gaglia MA
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):144-56. PubMed ID: 25079473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.